Biography
Dr. Fang Yu is a distinguished Chief Oncologist at Chinese PLA General Hospital (301) with 27 years of dedicated clinical practice. Over the course of an extensive career, Fang Yu has treated thousands of international and domestic patients, establishing a reputation for clinical excellence, evidence-based decision-making, and compassionate, family-centered care.
Clinical Focus & Expertise
Dr. Fang Yu specializes in the diagnosis and management of complex medical conditions, with particular expertise in Colorectal cancer, Targeted therapy, Hepatocellular carcinoma, Lung cancer. The clinical practice combines current best-evidence medicine with personalized treatment planning — recognizing that every patient brings a unique medical history, lifestyle, and set of life priorities to the consultation room.
Conditions Treated
Patients consult Dr. Fang Yu for the following conditions and procedures:
- Colorectal cancer
- Targeted therapy
- Hepatocellular carcinoma
- Lung cancer
Education & Training
- MD Sun Yat-sen University · Fellowship Princess Margaret Cancer Centre Toronto
Professional Credentials & Memberships
- Chinese Society of Clinical Oncology Member
- International Association for the Study of Lung Cancer
- European Society for Medical Oncology (ESMO)
International Patient Care
Dr. Fang Yu communicates with patients in English, Chinese, Spanish, providing direct rapport without the need for translation in those languages. The hospital's international department coordinates dedicated case managers, multilingual interpreters for additional languages, simplified visa documentation, and personalized treatment itineraries for travelers from over 60 countries.
“Every patient deserves more than a diagnosis — they deserve a treatment plan that respects who they are, where they come from, and what matters most to them.”
Education
MD Sun Yat-sen University · Fellowship Princess Margaret Cancer Centre Toronto
Certifications
- Chinese Society of Clinical Oncology Member
- International Association for the Study of Lung Cancer
- European Society for Medical Oncology (ESMO)